CM
INSM icon

Crestline Management’s Insmed INSM Stock Holding History

Crestline Management’s Portfolio INSM Stock Details INSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-68,856
Closed -$2.15M – 233
2017
Q4 		$2.15M Buy
68,856
+3,437
+5% +$102K 0.22% 36
2017
Q3 		$2.04M Buy
+65,419
New +$1.25M 0.28% 63

Other funds holding INSM

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Crestline Management's INSM Position: Q1 2018 in Review

Crestline Management sold out of Insmed (INSM) in Q1 2018, closing a stake of 68,856 shares — an estimated $2.15M sold.

Crestline Management first reported a position in INSM in Q3 2017 and held it in 2 quarters. The position peaked at $2.15M in Q4 2017. 127 funds tracked by Wall St. Rank hold INSM as of Q1 2018.

  • Crestline Management reported no remaining Insmed position as of Q1 2018 after selling out during the quarter.
  • Crestline Management sold 68,856 Insmed shares in Q1 2018, an estimated $2.15M.
  • Crestline Management first reported a position in Insmed in Q3 2017 and held it in 2 quarters.
  • Crestline Management's Insmed position peaked at $2.15M in Q4 2017.
  • 127 funds tracked by Wall St. Rank held Insmed as of Q1 2018.

Based on Crestline Management's 13F filing for Q1 2018, filed 15 May 2018.